Why The Market Is Dangerously Wrong About Pfizer Stock

Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum despite negative market sentiment and recent stock underperformance. Aggressive cost-cutting, targeting $7.7 billion in savings, is driving massive operating leverage and led PFE management to raise its full-year 2025 EPS guidance. Pfizer is successfully pivoting from COVID dependence. Its non-COVID portfolio, led by oncology and rare disease drugs, is now driving strong top-line growth.